Suppr超能文献

马波沙星对大肠杆菌体外活性的药效动力学模型。

Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains.

机构信息

Anses Laboratoire de Fougères, BP 90203, Fougeres, France.

出版信息

Antimicrob Agents Chemother. 2011 Feb;55(2):756-61. doi: 10.1128/AAC.00865-10. Epub 2010 Nov 15.

Abstract

A mathematical pharmacodynamic model was developed to describe the bactericidal activity of marbofloxacin against Escherichia coli strains with reduced susceptibility levels (determined using MICs) under optimal and intestinal growth conditions. Model parameters were estimated using nonlinear least-square curve-fitting procedures for each E. coli strain. Parameters related to bactericidal activity were subsequently analyzed using a maximum-effect (E(max)) model adapted to account for a direct and a delayed effect. While net growth rates did not vary significantly with strain susceptibility, culture medium had a major effect. The bactericidal activity of marbofloxacin was closely associated with the concentration and the duration of exposure of the bacteria to the antimicrobial agent. The value of the concentration inducing a half-maximum effect (C(50)) was highly correlated with MIC values (R(2) = 0.87 and R(2) = 0.94 under intestinal and optimal conditions, respectively). Our model reproduced the time-kill kinetics with good accuracy (R(2) of >0.90) and helped explain observed regrowth.

摘要

建立了一个数学药效动力学模型,用于描述马波沙星对最低抑菌浓度(MIC)测定的敏感性降低的大肠杆菌菌株在最佳和肠道生长条件下的杀菌活性。使用非线性最小二乘曲线拟合程序对每种大肠杆菌菌株进行模型参数估计。使用最大效应(E(max))模型对与杀菌活性相关的参数进行了分析,该模型经过调整可考虑直接和延迟作用。虽然净生长速率与菌株敏感性没有显著差异,但培养基有很大的影响。马波沙星的杀菌活性与细菌接触抗菌剂的浓度和时间密切相关。引起半最大效应的浓度(C(50))值与 MIC 值高度相关(肠道条件下为 R(2)= 0.87,最佳条件下为 R(2)= 0.94)。我们的模型很好地再现了时间杀伤动力学(R(2)值大于 0.90),并有助于解释观察到的复苏。

相似文献

1
Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains.
Antimicrob Agents Chemother. 2011 Feb;55(2):756-61. doi: 10.1128/AAC.00865-10. Epub 2010 Nov 15.
2
3
Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.
Antimicrob Agents Chemother. 2006 Nov;50(11):3779-85. doi: 10.1128/AAC.00711-05. Epub 2006 Aug 28.
8
Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease.
J Vet Pharmacol Ther. 2012 Dec;35(6):519-28. doi: 10.1111/j.1365-2885.2011.01350.x. Epub 2011 Nov 29.

引用本文的文献

3
Modeling the Growth and Death of against Essential Oil at Different pH Conditions.
Antibiotics (Basel). 2021 Feb 23;10(2):222. doi: 10.3390/antibiotics10020222.
4
Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents.
J Vet Sci. 2019 Sep;20(5):e40. doi: 10.4142/jvs.2019.20.e40.
6
PK-PD Integration Modeling and Cutoff Value of Florfenicol against in Pigs.
Front Pharmacol. 2018 Jan 17;9:2. doi: 10.3389/fphar.2018.00002. eCollection 2018.
7
Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against in Pigs.
Front Pharmacol. 2017 Aug 21;8:542. doi: 10.3389/fphar.2017.00542. eCollection 2017.
10
Pharmacokinetic-pharmacodynamic model to evaluate intramuscular tetracycline treatment protocols to prevent antimicrobial resistance in pigs.
Antimicrob Agents Chemother. 2015 Mar;59(3):1634-42. doi: 10.1128/AAC.03919-14. Epub 2014 Dec 29.

本文引用的文献

1
Pharmacokinetic/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole-Candida interactions.
Int J Antimicrob Agents. 2009 Sep;34(3):240-5. doi: 10.1016/j.ijantimicag.2009.02.006. Epub 2009 Mar 31.
2
PK/PD: new insights for antibacterial and antiviral applications.
Curr Opin Pharmacol. 2008 Oct;8(5):549-56. doi: 10.1016/j.coph.2008.06.010. Epub 2008 Jul 30.
3
Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli.
J Antimicrob Chemother. 2008 Sep;62(3):495-503. doi: 10.1093/jac/dkn222. Epub 2008 Jun 10.
4
A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro.
Int J Antimicrob Agents. 2008 Apr;31(4):369-74. doi: 10.1016/j.ijantimicag.2007.11.015. Epub 2008 Jan 22.
5
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains.
Int J Antimicrob Agents. 2007 Mar;29(3):263-70. doi: 10.1016/j.ijantimicag.2006.08.049. Epub 2006 Dec 27.
6
7
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
J Antimicrob Chemother. 2005 May;55(5):601-7. doi: 10.1093/jac/dki079. Epub 2005 Mar 16.
8
Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
Int J Antimicrob Agents. 2005 Feb;25(2):120-9. doi: 10.1016/j.ijantimicag.2004.09.012.
9
Novel concentration-killing curve method for estimation of bactericidal potency of antibiotics in an in vitro dynamic model.
Antimicrob Agents Chemother. 2004 Oct;48(10):3884-91. doi: 10.1128/AAC.48.10.3884-3891.2004.
10
Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.
Antimicrob Agents Chemother. 2004 Oct;48(10):3670-6. doi: 10.1128/AAC.48.10.3670-3676.2004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验